In the last 25 years, HIV-1, the retrovirus responsible for the acquired immunodeficiency
syndrome (AIDS), has gone from being an “inherently untreatable” infectious agent to one …

The lentivirus human immunodeficiency virus (HIV) causes AIDS by interacting with a large
number of different cells in the body and escaping the host immune response against it. HIV …

The anti-HIV chemotherapy era started a decade ago when suramin was found to protect
human T lympho-cytes against the infectivity and cytopathicity of human immunodeficiency …

The development of antiretroviral therapy against acquired immunodeficiency syndrome
(AIDS) has been an intense research effort since the discovery of the causative agent …

Background Significant pain from HIV-associated sensory neuropathy (HIV-SN) affects∼
40% of HIV infected individuals treated with antiretroviral therapy (ART). The prevalence of …

The use of N-type voltage-gated calcium channel (CaV2. 2) blockers to treat pain is limited
by many physiological side effects. Here we report that inflammatory and neuropathic …

3′-Azido-2′, 3′-dideoxythymidine (AZT) and 2′, 3′-didehydro-2′, 3′-
dideoxythymidine (D4T) are potent and selective inhibitors of human immunodeficiency …

Over the last 10 years the appreciation of the full breadth of the spectrum of human
immunodeficiency virus (HIV) infection has gradually increased; it is now known that AIDS …

A set of mutations [Ala-62--> Val (A62V), V75I, F77L, F116Y, and Q151M] in the polymerase
domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) …

The HIV/AIDS pandemic is an increasing global burden with devastating health-related and
socioeconomic effects. The widespread use of antiretroviral therapy has dramatically …